<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03000127</url>
  </required_header>
  <id_info>
    <org_study_id>1R01NS102295</org_study_id>
    <nct_id>NCT03000127</nct_id>
  </id_info>
  <brief_title>Testosterone for Fatigue in Men With MS</brief_title>
  <official_title>A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fatigue is a major symptom in people with multiple sclerosis (MS), for which treatments are
      limited. Several studies have shown that a large proportion of men with MS have low
      testosterone levels. We propose a two-site clinical trial using topical testosterone gel as a
      treatment for MS-related fatigue in men with progressive MS who have low or low-normal
      testosterone levels.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, testosterone or placebo will be administered to all patients at some period of study, but which period of study the they will recieve placebo or testosterone gel will be blinded (unknown) to participant, care provider, and outcomes assessor.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All patients will receive either testosterone or placebo at some phase of treatment, but which phase will be testosterone and which will be placebo will be unknown (blinded) to participant, care provider, and outcomes assessor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Fatigue Impact Scale (MFIS)</measure>
    <time_frame>18 months</time_frame>
    <description>assessment of fatigue severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Localized Gray Matter Atrophy</measure>
    <time_frame>18 months</time_frame>
    <description>Quantify effect of testosterone treatment on localized gray matter atrophy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Axon Density in White Matter</measure>
    <time_frame>18 months</time_frame>
    <description>Quantify effect of testosterone treatment on axon density in major white matter tracts</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of testosterone level with fatigue</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of localized gray matter atrophy with fatigue</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of axon density in white matter with fatigue</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Single arm crossover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive testosterone gel and placebo gel during some months, but the months that they are on each treatment will be unknown to the patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AndroGel 1 % Topical Gel</intervention_name>
    <description>testosterone gel</description>
    <arm_group_label>Single arm crossover</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo gel</description>
    <arm_group_label>Single arm crossover</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1) Men with SPMS or PPMS, 2)18-60 years old, 3) EDSS of 1.0- 6.5, 4) Low or low-normal T &lt;
        499ng/dL and 5) FSS scores of &gt;3.6.

        Exclusion Criteria:

        1) Prostate specific antigen &gt; 2.5 (&lt;49yr of age) or &gt;3.5 (age &gt;50yr of age), 2) baseline
        hematocrit greater than the upper limit of normal for the laboratory used, 3) EKG with
        ischemic changes, 4) history of myocardial infarction, unstable angina, stroke, transient
        ischemic attack, or deep vein thrombosis, 5) history of prostate or breast cancer, 6)
        screening T level &gt;500ng/dL, 7) diabetes requiring treatment, 8) current drug/alcohol
        abuse, 9) disease other than MS causing fatigue, such as obstructive sleep apnea or other
        sleep disorder, or untreated thyroid dysfunction, 10) RRMS, 11) Beck Depression
        Inventory-II (BDI) score over 20, 12) cognitive dysfunction such that subject cannot
        perform study tests, 13) inability to undergo MRI, 14) current or expected use of
        amphetamines, or 15) anticipated changes in medical treatments that might affect fatigue
        scores (e.g., expected changes in spasticity, sleep, or depression medications).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mike Montag, M.S.</last_name>
      <phone>310-206-2176</phone>
      <email>MMontag@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Rhonda Voskuhl, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sicotte NL, Giesser BS, Tandon V, Klutch R, Steiner B, Drain AE, Shattuck DW, Hull L, Wang HJ, Elashoff RM, Swerdloff RS, Voskuhl RR. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol. 2007 May;64(5):683-8.</citation>
    <PMID>17502467</PMID>
  </reference>
  <reference>
    <citation>Kurth F, Luders E, Sicotte NL, Gaser C, Giesser BS, Swerdloff RS, Montag MJ, Voskuhl RR, Mackenzie-Graham A. Neuroprotective effects of testosterone treatment in men with multiple sclerosis. Neuroimage Clin. 2014 Mar 6;4:454-60. doi: 10.1016/j.nicl.2014.03.001. eCollection 2014.</citation>
    <PMID>24634831</PMID>
  </reference>
  <reference>
    <citation>Gold SM, Chalifoux S, Giesser BS, Voskuhl RR. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflammation. 2008 Jul 31;5:32. doi: 10.1186/1742-2094-5-32.</citation>
    <PMID>18671877</PMID>
  </reference>
  <reference>
    <citation>Ziehn MO, Avedisian AA, Dervin SM, Umeda EA, O'Dell TJ, Voskuhl RR. Therapeutic testosterone administration preserves excitatory synaptic transmission in the hippocampus during autoimmune demyelinating disease. J Neurosci. 2012 Sep 5;32(36):12312-24. doi: 10.1523/JNEUROSCI.2796-12.2012.</citation>
    <PMID>22956822</PMID>
  </reference>
  <reference>
    <citation>Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res. 2009;175:239-51. doi: 10.1016/S0079-6123(09)17516-7. Review.</citation>
    <PMID>19660660</PMID>
  </reference>
  <reference>
    <citation>Liva SM, Voskuhl RR. Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J Immunol. 2001 Aug 15;167(4):2060-7.</citation>
    <PMID>11489988</PMID>
  </reference>
  <reference>
    <citation>Dalal M, Kim S, Voskuhl RR. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol. 1997 Jul 1;159(1):3-6.</citation>
    <PMID>9200430</PMID>
  </reference>
  <reference>
    <citation>Golden LC, Voskuhl R. The importance of studying sex differences in disease: The example of multiple sclerosis. J Neurosci Res. 2017 Jan 2;95(1-2):633-643. doi: 10.1002/jnr.23955. Review.</citation>
    <PMID>27870415</PMID>
  </reference>
  <reference>
    <citation>Spence RD, Voskuhl RR. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front Neuroendocrinol. 2012 Jan;33(1):105-15. doi: 10.1016/j.yfrne.2011.12.001. Epub 2011 Dec 24. Review.</citation>
    <PMID>22209870</PMID>
  </reference>
  <reference>
    <citation>Hussain R, Ghoumari AM, Bielecki B, Steibel J, Boehm N, Liere P, Macklin WB, Kumar N, Habert R, Mhaouty-Kodja S, Tronche F, Sitruk-Ware R, Schumacher M, Ghandour MS. The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination. Brain. 2013 Jan;136(Pt 1):132-46. doi: 10.1093/brain/aws284.</citation>
    <PMID>23365095</PMID>
  </reference>
  <reference>
    <citation>Voskuhl RR, Gold SM. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol. 2012 Mar 27;8(5):255-63. doi: 10.1038/nrneurol.2012.43. Review.</citation>
    <PMID>22450508</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2016</study_first_submitted>
  <study_first_submitted_qc>December 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2016</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Rhonda Voskuhl</investigator_full_name>
    <investigator_title>Professor, Department of Neurology</investigator_title>
  </responsible_party>
  <keyword>testosterone</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

